March 18, 2008 - Sernova Corp. (TSX-V: SVA) is pleased to announce that the company will be meeting with the United States Food and Drug Administration (FDA) on April 25, 2008 regarding Sertolin, the company's investigational cellular therapy being developed for diabetes treatment. This formal pre-Investigational New Drug (IND) meeting is Sernova's first step in seeking IND approval to initiate clinical trials in humans. The FDA meeting will provide Sernova with the opportunity to present its experimental data on Sertolin, obtain feedback on its pre-clinical data package, and receive the FDA's perspective on its proposed clinical strategy... Sernova's Press Release -
Showing posts with label Sernova. Show all posts
Showing posts with label Sernova. Show all posts
Tuesday, March 18, 2008
Sernova, First Regulatory Step Towards Clinical Trials-Granted Formal Pre-IND Meeting With FDA
March 18, 2008 - Sernova Corp. (TSX-V: SVA) is pleased to announce that the company will be meeting with the United States Food and Drug Administration (FDA) on April 25, 2008 regarding Sertolin, the company's investigational cellular therapy being developed for diabetes treatment. This formal pre-Investigational New Drug (IND) meeting is Sernova's first step in seeking IND approval to initiate clinical trials in humans. The FDA meeting will provide Sernova with the opportunity to present its experimental data on Sertolin, obtain feedback on its pre-clinical data package, and receive the FDA's perspective on its proposed clinical strategy... Sernova's Press Release -
Tuesday, September 11, 2007
Sernova, Sertoli Cells Successfully Engineered to Secrete Insulin, Effective in Preclinical Models of Diabetes
September 10, 2007 - Sernova Corp. (TSX-V: SVA) would like to congratulate Dr. Jannette Dufour and Ms. Katie Halley who have reversed diabetes in an animal model by genetically engineering Sertoli cells to secrete insulin... Sernova's Press Release -
Subscribe to:
Posts (Atom)
